In the past week, ONCY stock has gone down by -14.71%, with a monthly decline of -6.67% and a quarterly plunge of -32.17%. The volatility ratio for the week is 7.28%, and the volatility levels for the last 30 days are 8.96% for Oncolytics Biotech, Inc The simple moving average for the last 20 days is -11.69% for ONCY stock, with a simple moving average of -24.25% for the last 200 days.
Is It Worth Investing in Oncolytics Biotech, Inc (NASDAQ: ONCY) Right Now?
Moreover, the 36-month beta value for ONCY is 1.27. Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy,” 5 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ONCY is 76.02M and currently, short sellers hold a 3.70% of that float. On January 15, 2025, ONCY’s average trading volume was 468.20K shares.
ONCY) stock’s latest price update
Oncolytics Biotech, Inc (NASDAQ: ONCY) has seen a decline in its stock price by -3.70 in relation to its previous close of 0.81. However, the company has experienced a -14.71% decline in its stock price over the last five trading sessions. prnewswire.com reported 2025-01-15 that New pancreatic cancer cohort moves forward with full enrollment of 30 patients in Stage 1 SAN DIEGO and CALGARY, AB, Jan. 15, 2025 /PRNewswire/ — Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that Germany’s medical regulatory body, the Paul-Ehrlich-Institute (PEI), has approved the continuation of patient enrollment into Cohort 5 of the GOBLET study. This cohort is evaluating pelareorep in combination with modified FOLFIRINOX (mFOLFIRINOX) with or without atezolizumab (Tecentriq®) in newly diagnosed pancreatic ductal adenocarcinoma (PDAC) patients.
Analysts’ Opinion of ONCY
Many brokerage firms have already submitted their reports for ONCY stocks, with Maxim Group repeating the rating for ONCY by listing it as a “Buy.” The predicted price for ONCY in the upcoming period, according to Maxim Group is $3 based on the research report published on October 06, 2022 of the previous year 2022.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see ONCY reach a price target of $15. The rating they have provided for ONCY stocks is “Buy” according to the report published on February 17th, 2021.
ONCY Trading at -17.09% from the 50-Day Moving Average
After a stumble in the market that brought ONCY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -49.02% of loss for the given period.
Volatility was left at 8.96%, however, over the last 30 days, the volatility rate increased by 7.28%, as shares sank -0.48% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -29.59% lower at present.
During the last 5 trading sessions, ONCY fell by -11.46%, which changed the moving average for the period of 200-days by -23.61% in comparison to the 20-day moving average, which settled at $0.8846. In addition, Oncolytics Biotech, Inc saw -14.64% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ONCY
The total capital return value is set at -2.13. Equity return is now at value -144.22, with -78.05 for asset returns.
Based on Oncolytics Biotech, Inc (ONCY), the company’s capital structure generated 0.11 points at debt to capital in total, while cash flow to debt ratio is standing at -17.32.
Currently, EBITDA for the company is -33.71 million with net debt to EBITDA at 0.53. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.99.
Conclusion
To wrap up, the performance of Oncolytics Biotech, Inc (ONCY) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
